Publications:

Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2- Breast Cancer Patient With High Tumor Mutational Burden.

Frontiers In Oncology

Wang, Rong R; Yang, Yuchen Y; Ye, Wei-Wu WW; Xiang, Jianxing J; Chen, Songan S; Zou, Wei-Bin WB; Wang, Xiao-Jia XJ; Chen, Tianhui T; Cao, Wen-Ming WM

Publication Date: 2020

Variant appearance in text: KMT2C: 12392G>A; Arg4131Lys

PubMed Link: 33634015

Variant Present in the following documents:

• Table_1.xlsx, sheet 8

View BVdb publication page